Andrew D. Skibo is Head of Global Biologics Operations & Global Engineering at MedImmune/AstraZeneca where he affects changes in manufacturing operations, quality oversight, and cross-functional relations throughout the company. He is also responsible for AstraZeneca’s Global Engineering and Real Estate functions. Previously he has worked in other senior leadership roles at Amgen, Genentech, and Foster Wheeler, among others. In these roles he has been responsible for significant aspects of the companies’ operations including operations, engineering, construction, and validation for large-scale capital projects related to bio-pharmaceutical manufacturing. He is a member of the International Leadership Forum (ILF), a member of the Materials Technical Advisory Committee of the US Department of Commerce, and a member of the Editorial Advisory Board of Life Science Leader. As an ISPE Member for 24 years Andy Skibo has served on the judging panel for the Facility of the Year Award, he has been a conference leader, and he participates on several committees. He was elected to the ISPE International Board of Directors in 2011. Andy Skibo holds a BS in Organic Chemistry and an MS in Chemical Engineering, both from MIT.